The global network led by the Oxford Maternal and Perinatal Health Institute (OMPHI) at the University of Oxford has today published, in The Lancet, the results of the \u20182022 INTERCOVID Study\u2019 conducted in 41 hospitals across 18 countries.
A 35-page full-colour report was sent out to hundreds of donors as a thank you for their important contributions, and to show them the difference they helped to make during the pandemic.
Researchers from Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences (NDORMS) at the University of Oxford have investigated claims that some adenovirus-based COVID-19 vaccines increase the risk of rare blood clots compared to their mRNA-based counterparts.
COVID-19 has caused a protracted shock to life expectancy levels, leading to global mortality changes unprecedented in the last 70 years, according to research published in Nature Human Behaviour from Oxford\u2019s Leverhulme Centre for Demographic Science and the Max Planck Institute for Demographic Research.
Researchers from the University of Oxford have today reported new findings from a study exploring how certain genes can help generate a strong immune response following vaccination with two commonly used COVID-19 vaccines \u2013 identifying a particular gene associated with a high antibody response.
A new study led by Oxford researchers found that prior COVID-19 infection was associated with more uneven inflation of the lungs during normal breathing, smaller lung volumes, and greater respiratory dead space.
When the University of Oxford developed a vaccine that was effective against COVID-19, ensuring that it could be rolled out globally and in perpetuity for low- and middle-income countries was of paramount importance.
Up to $30 million in funding has been announced by the Coalition for Epidemic Preparedness Innovations (CEPI) to bring a new nanoparticle vaccine offering protection against a range of coronaviruses to clinical trial.
Two doses of the COVID-19 vaccine are effective against severe disease for people who are underweight, overweight, or who have obesity, finds new research published in The Lancet Diabetes and Endocrinology, led by researchers at the University of Oxford.
The Oxford Clinical Trials Research Unit at Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences (NDORMS) played a key role in the Vaccine Response On Off Methotrexate (VROOM) study which found that pausing immune-suppressing medicines such as methotrexate can increase the response to COVID-19 booster jabs.
Since the beginning of the pandemic, COVID has infected at least a third of the UK population and is estimated to have factored in the deaths of almost 200,000 people in the UK. But critically, COVID has also had a devastating impact on our healthcare systems. While this was expected, new evidence is beginning to reveal the scope of the issue \u2013 in particular the effects for people living with long-term health conditions.
People with certain inflammatory immune conditions affecting the joints, bowel and skin, such as rheumatoid arthritis, may have been more at risk of dying or needing hospital care if they got COVID-19 before vaccination compared with the general population, according to a new study published in The Lancet Rheumatology with the involvement of researchers from the University of Oxford.
While evidence suggests that people who are vaccinated before they get COVID are less likely to develop long COVID than unvaccinated people, the effectiveness of vaccination on existing long COVID has been less clear.
Researchers running the University of Oxford-led Com-COV programme have launched a further study of COVID-19 vaccination schedules in young people aged 12 to 15 \u2013 with a focus on assessing different options for a third dose booster vaccination.
COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.
COVID-19 vaccines given as fourth doses in the UK offer excellent boosting immunity protection, according to the latest results from a nationwide NIHR-supported study.
A recent study of patient health records found that around 1 in 100 people with COVID-19 had a venal or arterial thrombosis, with rates higher still among males, and particularly for those hospitalised.
One trial. Over 47,000 participants. Nearly 200 hospital sites, across six countries. Ten results. Four effective COVID-19 treatments. And behind them all, an army of countless researchers, doctors, nurses, statisticians and supporting staff.
Researchers from Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS) found no evidence that COVID-19 vaccines cause neurological disorders. But they did find an increased risk for unvaccinated people infected with SARS-CoV-2.
A new collaboration between Oxford, Brazil and Pakistan has been funded by the Bill & Melinda Gates Foundation. The partnership will provide researchers with de-identified health data from two of the worlds global COVID-19 hotspots to increase understanding of COVID-19 in these communities and help accelerate the management of the disease.
![\"Vaccines](\"https://www.medsci.ox.ac.uk/news/vaccination-shown-to-protect-against-pregnancy-complications-from-covid-19-omicron-variant/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n